KeyCare Deploys NVIDIA Nemotron to Power AI-Driven Clinical Intake at Scale
KeyCare, the nation’s only Epic‑based virtual care group, has launched NVIDIA’s Nemotron large language model in production to power its AI‑driven patient intake agent. The agent, embedded in KeyCare’s virtual waiting room, captures and summarizes clinically relevant Epic data before the encounter, allowing clinicians to focus on assessment. Early data show a 15‑30% boost in provider efficiency for common urgent‑care visits such as respiratory and urinary‑tract infections. KeyCare plans to extend NVIDIA‑powered AI agents to routing, operations and patient support across its 50‑state network.
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
Alnylam Pharmaceuticals announced a strategic partnership with Viz.ai to develop an AI‑enabled care pathway for earlier detection of transthyretin amyloid cardiomyopathy (ATTR‑CM), launching the AWARE study in five health systems. The company also pledged support for the American Heart Association’s...
OnMed Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
OnMed has been named to Fast Company’s World’s Most Innovative Companies list for 2026, earning a No. 14 ranking in North America. The company’s AI‑enabled CareStation™ platform has expanded into rural states, schools, an airport hub, and Puerto Rico over the...
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals announced that the pivotal Phase 3 LUCIDITY trial of avexitide has completed enrollment, randomizing and dosing the final participant to bring the total to 78 patients across 21 U.S. sites. The double‑blind, placebo‑controlled study evaluates avexitide, a first‑in‑class GLP‑1...
Experian Health’s 2026 State of Patient Access Survey Reveals Patient Experience Is Improving, but Big Challenges Remain for Healthcare Providers
Experian Health’s 2026 State of Patient Access Survey shows modest gains in perceived access, with 46% of providers saying access improved versus only 18% of patients. Operational efficiencies and digital tools are helping, but staffing shortages now affect 64% of...
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR)...
Mosaic Therapeutics will present preclinical data on its lead program MOS101—a combination of the next‑generation MDM2 antagonist ASTX295 and the FDA‑approved PARP inhibitor olaparib—at the AACR 2026 Annual Meeting. The poster focuses on BRCA2‑mutant, TP53‑wild‑type solid tumours and highlights the...
Palm Primary Care Expands in Tarrant County with Acquisition of Two Clinics in Azle
Palm Primary Care, backed by MBF Healthcare Partners II, has acquired two primary‑care clinics in Azle, Texas, expanding its Texas network to nine locations across Tarrant and Dallas counties. The two sites, Azle Central and Azle Parkway, will continue operating...
Integrated DNA Technologies Expands Into Clinical Diagnostics with First In Vitro Diagnostic
Integrated DNA Technologies (IDT) announced the launch of two in‑vitro diagnostic kits, Archer FUSION Plex‑HT Dx and VARIANT Plex‑HT Dx, marking its entry into the next‑generation sequencing (NGS) IVD market. Built on IDT’s proprietary anchored multiplex PCR chemistry, the kits offer targeted DNA and RNA...
Matrix Providers Inc. Announces Leadership Transition: Founder Dr. Bill Rivard to Become Chairman; Tricia Brown Named CEO
Matrix Providers Inc. announced that founder and CEO Dr. Bill Rivard will become Chairman of the Board on April 1, 2026, while President and COO Tricia Brown will step up as President and CEO. Rivard, who founded the company in...
Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business
Cencora, Inc. announced a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, integrating the physicians into its Retina Consultants of America (RCA) network. The acquisition is expected to be slightly accretive to adjusted diluted EPS within the first...
Oryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease
Oryon Cell Therapies presented interim Phase 1b/2a data showing that its autologous dopaminergic neuron‑replacement therapy produced sustained motor improvements in Parkinson’s patients. Five participants experienced 29‑62% reductions in OFF‑state MDS‑UPDRS Part III scores over 6‑18 months, with continued gains beyond six months....
Latent-Y: The Autonomous AI Agent for Drug Design at Scale
Latent Labs unveiled Latent‑Y, an autonomous AI agent that designs therapeutic antibodies from natural‑language prompts. Powered by the Latent‑X2 generative model, the platform compresses weeks of expert work into hours and can run multiple design campaigns in parallel. In three...
Almirall’s 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in...
Almirall hosted its 17th Skin Academy in Barcelona and Prague, drawing 800 dermatology professionals to discuss the latest science in medical dermatology. The program spotlighted new insights into atopic dermatitis—especially facial and neck involvement—and psoriasis, emphasizing patient‑reported outcomes and holistic...
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing
Galderma announced that the U.S. FDA has cleared Restylane Contour for the correction of temple hollowing in adults over 21, extending its existing cheek and mid‑face indications. Clinical studies demonstrated a 91% responder rate at three months, with efficacy persisting for...
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Prothena and its partners Roche and Bristol Myers Squibb presented late‑stage data on two neurodegenerative candidates at AD/PD™ 2026. Prasinezumab demonstrated a roughly two‑year delay in Parkinson’s disease progression, sustained motor benefits in the PADOVA open‑label extension, and favorable imaging and...
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
ImmunityBio secured its first Asian regulatory clearance as the Macau Special Administrative Region approved ANKTIVA® for BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The decision leveraged prior FDA and EMA approvals, illustrating a...
Health Gorilla and GuardDog Telehealth Set the Record Straight
Health Gorilla released a case study and 21 recorded meetings showing GuardDog consistently described its services as treatment‑focused telehealth. The materials confirm GuardDog’s claim that all data queries were made under HIPAA authorizations to support patient care, not for non‑treatment...
Fauna Bio Announces Target Designation Milestone in Obesity Discovery Collaboration
Fauna Bio announced that its Convergence™ AI platform has achieved a target designation milestone in its obesity discovery partnership with Eli Lilly, triggering a contractual payment. The designated target stems from comparative genomics of over 450 mammal species, especially hibernators,...
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
Glaukos announced that Epioxa™ HD/Epioxa™ is now commercially available, marking the first FDA‑approved, incision‑free topical drug for keratoconus. The therapy uses a riboflavin solution with the O₂n™ System and Boost Goggles, eliminating the need to remove the corneal epithelium. By...
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
Pfizer announced that the Phase 3 TALAPRO‑3 trial met its primary endpoint, showing that TALZENNA (talazoparib) combined with XTANDI (enzalutamide) significantly improved radiographic progression‑free survival (rPFS) in patients with HRR gene‑mutated metastatic hormone‑sensitive prostate cancer. The combination achieved a hazard ratio...
INSTEM Announces Extension of Research Collaboration Agreement with U.S. FDA to 2031
Instem, a global SaaS leader for life‑science R&D, announced a five‑year extension of its Research Collaboration Agreement with the U.S. Food and Drug Administration, now running through February 2031. The partnership, originally launched in 2011, has become a cornerstone of FDA‑aligned...
UK-First AI Case-Finding Pathway Launched to Improve Early Detection of Oesophageal and Gastric Cancer
A new NHS‑first AI‑enabled case‑finding pathway has launched in North East Essex to detect oesophageal and gastric cancers earlier. The programme, built on the C the Signs platform, analyses routine electronic health records and patient‑reported data to flag high‑risk individuals....
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) From Merck Animal Health to Treat and Control Asian Longhorned Tick...
Merck Animal Health announced that the FDA has approved an expanded label for its once‑yearly injectable parasite control, Bravecto Quantum, adding treatment and control of Asian longhorned tick (Haemaphysalis longicornis) and Gulf Coast tick (Amblyomma maculatum) for 12 months. The product...
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
NeoGenomics announced that its PanTracer™ LBx liquid biopsy test has received Medicare coverage under CMS’s MolDX program. The CLIA‑certified assay profiles more than 500 genes, including MSI and blood‑tumor mutational burden, with a seven‑day turnaround. Coverage allows Medicare beneficiaries to...
UnitedHealthcare Expands Doula Offering to Employer-Sponsored Plans Nationwide
UnitedHealthcare announced a nationwide rollout of its Doula Support program for employer‑sponsored health plans, potentially reaching 7.2 million members by January 1, 2027. The benefit gives members the option to engage doulas in‑person or virtually throughout pregnancy, birth, and postpartum. UnitedHealthcare estimates its...
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-Severe Atopic Dermatitis
Almirall reported that lebrikizumab met both co‑primary endpoints in the Phase 3 ADorable‑1 trial, with 63% of pediatric participants achieving EASI‑75 and 44% attaining clear or almost clear skin (IGA 0/1) after 16 weeks. Key secondary outcomes showed significant itch reduction, higher...
L&T Technology Services Launches NVIDIA-Powered AI Lung Digital Twin Platform for Advanced Respiratory Diagnostics
L&T Technology Services (LTTS) unveiled an AI‑powered digital twin platform that creates immersive 3D models of patients’ lungs from CT scans. The solution leverages NVIDIA’s Physical AI stack—including Omniverse, TensorRT and MONAI—to deliver real‑time visualization, automated segmentation of airways, vessels...
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
Natera announced two peer‑reviewed studies demonstrating the clinical utility of its personalized ctDNA assay, Signatera, in anal squamous cell carcinoma and locally advanced rectal cancer. In the ASCC cohort of 84 patients, baseline negativity or clearance of ctDNA during chemoradiotherapy...
AHF Urges EU to Stop Blocking Health Equity
The AIDS Healthcare Foundation (AHF) Europe will stage an advocacy action and press conference in Brussels on March 18, 2026, urging the European Commission to adopt a legally binding Pathogen Access and Benefit‑Sharing (PABS) Annex to the WHO Pandemic Agreement. The organization...
RevnaBio Secures Triple International Laboratory Accreditation to Expand Precision Medicine and Clinical Research Infrastructure in Africa
RevnaBio received triple accreditation from the American Association for Laboratory Accreditation (A2LA) for ISO 15189, ISO 20387 and ISO/IEC 17043, validating its medical laboratory, biobanking and proficiency‑testing operations. The certifications boost diagnostic quality, enable local molecular testing, and provide a trusted platform for...
KERENDIA® (Finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
Bayer announced that Kerendia® (finerenone) met its primary endpoint in the Phase III FIND‑CKD trial, showing a statistically significant slowing of eGFR decline versus placebo in non‑diabetic chronic kidney disease patients. The study enrolled over 1,500 participants and represents the fifth...
Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-Acting Semaglutide
Samsung Bioepis and its sister firm Epis NexLab have signed a research collaboration and exclusive license agreement with G2GBIO to develop a long‑acting semaglutide formulation using G2GBIO’s proprietary microsphere technology. The deal grants Samsung Bioepis full rights to the semaglutide...
YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency...
YolTech Therapeutics announced FDA approval of its IND for YOLT-202, an in vivo adenine base‑editing therapy targeting Alpha‑1 Antitrypsin Deficiency. The clearance permits an open‑label, single‑dose Phase 2/3 expansion study across the U.S. and other regions. In the ongoing first‑in‑human trial,...
Advanced eClinical Training Expands Nationwide Clinical Partner Network, Strengthening Medical Assistant Workforce Pipeline
Advanced eClinical Training (ACT) announced that its clinical partner network now spans more than 1,000 healthcare sites across the United States, providing externship placements for students in its medical‑assistant, phlebotomy and allied‑health programs. The company’s extern‑to‑hire model lets providers evaluate...
ACCESS GPO Announces Preferred Strategic Commercial Agreement to Provide Affera™ Mapping and Ablation System with Sphere-9™ Catheter to Ambulatory Surgery...
ACCESS GPO has signed a multi‑year preferred agreement with Medtronic to supply the Affera™ Mapping and Ablation System, featuring the Sphere‑9™ catheter, to physician‑led ambulatory surgery centers across the United States. The partnership aims to accelerate adoption of pulsed field...
OpenFold Consortium Announces Major OpenFold3 Update and Public Release of Training Data for Reproducible Biomolecular AI
The OpenFold Consortium unveiled OpenFold3’s major update, releasing the full training datasets, model weights, code, and evaluation scripts via AWS’s Registry of Open Data. The open‑source co‑folding system now includes a dedicated portal with onboarding documentation and a public support...
Jackson Healthcare President Shane Jackson Honored on “Staffing 100” List of Leaders Shaping the Workforce Solutions Industry
Jackson Healthcare president Shane Jackson was named to the 2026 Staffing 100 North America list, marking his ninth consecutive appearance. During his tenure, the company added a dozen acquisitions, broadened its portfolio to include executive search, allied health, nursing, surgical services...
Western Alliance Bank Launches Healthcare Industry Specialization, Led by Industry Veteran Jennifer Hwang
Western Alliance Bank announced the launch of a dedicated Healthcare commercial banking team, headed by industry veteran Jennifer Hwang. The new unit will serve subsectors such as specialty pharmaceuticals, medical devices, home health, hospice, and ambulatory surgical centers. Leveraging the...
Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection
Aditxt, Inc. announced the acquisition of Ignite Proteomics for $36 million in Series A‑2 convertible preferred stock, adding a CLIA‑certified functional proteomics platform to its oncology portfolio. Ignite’s Reverse Phase Protein Array (RPPA) assay quantifies 32 phospho‑ and total‑protein biomarkers, offering therapy‑selection...
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should Be Accessible and...
Guardant Health released a Harris Poll showing 92% of Americans aged 45+ support no‑copay coverage for blood‑based colorectal cancer (CRC) screening. The survey highlighted anxiety around colonoscopies and disgust for stool tests as major barriers, while 77% said a FDA‑approved...
SoundHound at HIMSS26: How MUSC Health Turned a Staffing Crisis Into a Voice AI Success Story
SoundHound AI showcased its enterprise‑wide Amelia voice‑AI platform at HIMSS26, highlighting a massive deployment at MUSC Health. The system, branded Emily, has processed over 2.2 million calls across patient access, revenue cycle and pharmacy, automating one‑quarter of interactions and achieving a...
Heidi Arrives at HIMSS26 with R1 Partnership and a Platform Built Beyond the Scribe
Heidi used HIMSS26 to unveil its biggest product and partnership moves since launching its ambient AI scribe, announcing a revenue‑cycle integration with R1 and a new clinical‑evidence tool called Evidence. The company says the platform now handles over 2.7 million visits...
SS&C GlobeOp Hedge Fund Performance Index and Capital Movement Index
SS&C Technologies reported that its GlobeOp Hedge Fund Performance Index posted a 0.59% gross return for February 2026. The accompanying Capital Movement Index rose 0.87% in March, marking a 12‑month high of 129.47 points. The index, which tracks assets administered...
Heru Showcases PretestPro™ for the Heru VR-Powered Diagnostic Headset at Vision Expo
Heru unveiled PretestPro™ at Vision Expo, a VR‑powered diagnostic headset that completes four essential eye‑pre‑tests in under two minutes. The wearable platform merges visual field, near cover test, extraocular motility and quantitative pupillometry into a single, AI‑guided workflow, replacing multiple...
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
Alkermes plc announced the inaugural Alkermes Pathways APN Research Awards™, a competitive grant program offering up to $10,000 per project to licensed psychiatric‑mental health nurse practitioners researching schizophrenia or bipolar I disorder. The application window runs from March 16 to...
Baseimmune Announces Strategic Expansion Into Fibrosis with Lead Program Targeting Idiopathic Pulmonary Fibrosis (IPF)
Baseimmune announced a new fibrosis‑focused pipeline leveraging its computational protein design platform to create multi‑pathway immunotherapies, starting with idiopathic pulmonary fibrosis (IPF). The company aims to deliver proof‑of‑concept efficacy data for its lead IPF program in 2026‑2027, addressing the limitations...
Prodalim Strengthens Its Functional Platform to Enter the Fast-Growing Nutraceutical Market with the Acquisition of Sylvestre, a Market Leader in...
Prodalim announced the acquisition of Sylvestre, a Brazilian leader in botanical extracts, to bolster its functional ingredient portfolio. Sylvestre brings a catalog of more than 200 natural ingredients and advanced extraction capabilities. The deal accelerates Prodalim's push into the U.S....
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
Compass Pathways plc announced that its senior management will attend the Stifel 2026 Virtual CNS Forum on March 17‑18, 2026, and will take part in a fireside chat on March 18 at 10:30 am ET. The session will be streamed live...
Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets
Veristat announced an expansion of its regulatory and clinical‑trial services aimed at Chinese pharmaceutical and medical‑device companies seeking faster entry into European markets, as well as the United Kingdom, Switzerland, the United States, Canada and Australia. The CRO highlighted recent...
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive Β-Catenin:TCF Interaction, Receives FDA Orphan Drug Designation for...
Parabilis Medicines announced that the FDA has granted both Orphan Drug and Fast Track designations to zolucatetide, the first direct inhibitor of the β‑catenin:TCF interaction, for desmoid tumors. Early Phase 1/2 data showed a 100 % disease‑control rate in ten patients and...